Prevalence of Self-Reported Anosmia and Ageusia in Elderly Patients Who Had Been Previously Hospitalized by SARS-CoV-2: The LONG-COVID-EXP Multicenter Study

Author:

Fernández-de-las-Peñas César1ORCID,Ortega-Santiago Ricardo1ORCID,Cancela-Cilleruelo Ignacio1,Rodríguez-Jiménez Jorge1,Fuensalida-Novo Stella1ORCID,Martín-Guerrero José D.23ORCID,Pellicer-Valero Óscar J.4ORCID,Cigarán-Méndez Margarita5

Affiliation:

1. Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Alcorcón, Spain

2. Intelligent Data Analysis Laboratory, Department of Electronic Engineering, ETSE (Engineering School), Universitat de València (UV), 46100 Burjassot, Spain

3. Valencian Graduate School and Research Network of Artificial Intelligence (ValgrAI), 46022 València, Spain

4. Image Processing Laboratory (IPL), Universitat de València, Parc Científic, 46010 València, Spain

5. Department of Psychology, Universidad Rey Juan Carlos (URJC), 28922 Alcorcón, Spain

Abstract

We explored two different graph methods for visualizing the prevalence of self-reported post-COVID anosmia and ageusia in a large sample of individuals who had been previously hospitalized in five different hospitals. A cohort of 1266 previously hospitalized COVID-19 survivors participated. Participants were assessed at hospitalization (T0) and at three different follow-up periods: 8.4 (T1), 13.2 (T2), and 18.3 (T3) months after hospital discharge. They were asked about the presence of self-reported anosmia and ageusia that they attributed to infection. Anosmia was defined as a self-perceived feeling of complete loss of smell. Ageusia was defined as a self-perceived feeling of complete loss of taste. Data about hospitalization were recorded from medical records. The results revealed that the prevalence of anosmia decreased from 8.29% (n = 105) at hospitalization (T0), to 4.47% (n = 56) at T1, to 3.27% (n = 41) at T2, and 3.35% (n = 42) at T3. Similarly, the prevalence of ageusia was 7.10% (n = 89) at the onset of SARS-CoV-2 infection (T0), but decreased to 3.03% (n = 38) at T1, to 1.99% (n = 25) at T2, and 1.36% (n = 17) at T3. The Sankey plots showed that only 10 (0.8%) and 11 (0.88%) patients exhibited anosmia and ageusia throughout all the follow-ups. The exponential curves revealed a progressive decrease in prevalence, demonstrating that self-reported anosmia and ageusia improved in the years following hospitalization. The female sex (OR4.254, 95% CI 1.184–15.294) and sufferers of asthma (OR7.086, 95% CI 1.359–36.936) were factors associated with the development of anosmia at T2, whereas internal care unit admission was a protective factor (OR0.891, 95% CI 0.819–0.970) for developing anosmia at T2. The use of a graphical method, such as a Sankey plot, shows that post-COVID self-reported anosmia and ageusia exhibit fluctuations during the first years after SARS-CoV-2 infection. Additionally, self-reported anosmia and ageusia also show a decrease in prevalence during the first years after infection, as expressed by exponential bar plots. The female sex was associated with the development of post-COVID anosmia, but not ageusia, in our cohort of elderly patients previously hospitalized due to COVID-19.

Publisher

MDPI AG

Subject

General Medicine

Reference33 articles.

1. SARS-CoV-2 infection and multi-organ system damage: A review;Rabaan;Biomol. Biomed.,2023

2. Borges do Nascimento, I.J., O’Mathúna, D.P., von Groote, T.C., Abdulazeem, H.M., Weerasekara, I., Marusic, A., Puljak, L., Civile, V.T., Zakarija-Grkovic, I., and Pericic, T.P. (2021). International Network of Coronavirus Disease 2019 (InterNetCOVID-19). Coronavirus disease (COVID-19) pandemic: An overview of systematic reviews. BMC Infect. Dis., 21.

3. Is loss of sense of smell a diagnostic marker in COVID-19: A systematic review and meta-analysis;Rocke;Clin. Otolaryngol.,2020

4. Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19;Struyf;Cochrane Database Syst. Rev.,2022

5. The association of “loss of smell” to COVID-19: A systematic review and meta-analysis;Aziz;Am. J. Med. Sci.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3